Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Confirms Trial Weighted Towards Overall Survival Endpoint

Analysts are keen to know more about the statistical weighting of Roche’s SKYSCRAPER 1 study of the TIGIT inhibitor, while Merck & Co can learn from their rival’s slip-up for their own trial design.

Roche
The leader in the TIGIT inhibitor field, Roche is banking on the SKYSCRAPER 1 study results turning positive at its next analysis • Source: Shutterstock

After two major setbacks in Phase III studies, doubts are growing about Roche’s TIGIT inhibitor candidate tiragolumab’s chances of success - but the company insists the drug can still deliver in non-small-cell lung cancer (NSCLC).

Roche’s SKYSCRAPER 1 study of tiragolumab in combination with its anti-PDL1 checkpoint inhibitor, Tecentriq (atezolizumab), in NSCLC produced its first...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category